Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Pulse Biosciences, Inc.NASDAQ: PLSE

Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other current liabilities rises 86.0% from a year ago

Other current liabilities stood at $6.46M at the end of Q2 FY2026, up 86.0% from a year earlier and up 96.7% from the prior quarter. Over 3 fiscal years it compounded at +217.3% a year.

Context

  • Other current liabilities amounted to 5.6% of total assets at the end of Q2 FY2026, up 2.7 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +86.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.46M+96.7% QoQ
Last fiscal yearDec 2025
$1.6M+33.5% YoY
Year agoJun 2025
$3.47M+86.0% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.0%——
1 year+33.5%——
3-year CAGR+217.3%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
1.6M USD
Year-over-year change
+33.5%
4-year CAGR
+2.3%

Other Current Liabilities vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +86.0% is the 2nd highest of 10, against a peer median of +26.0%.
  • Other current liabilities amounts to 5.6% of total assets for PLSE, versus a peer median of 2.5%.
PLSE Competitors
Other Current Liabilities for PLSE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVCRNovoCure LimitedMar 2026$90.34M USD——11.5%
OPKOPKO Health, Inc.Mar 2026$41.02M USD-8.9%+27.1%2.2%
STAASTAAR Surgical CompanyApr 2026$32.96M USD+26.0%+16.3%7.3%
NKTRNektar TherapeuticsJun 2026$16.36M USD+149.7%+32.5%1.5%
KMTSKestra Medical Technologies, Ltd.Jan 2026$10.24M USD+52.3%—2.7%
BBNXBeta Bionics, Inc.Mar 2026$8.34M USD+14.0%+122.5%2.7%
PLSEPulse Biosciences, Inc.Jun 2026$6.46M USD+86.0%+217.3%5.6%
DNTHDianthus Therapeutics, Inc.Jun 2026$5.61M USD+47.5%+65.9%0.5%
IMTXImmatics N.V.Mar 2026€5.24M EUR-20.0%-46.0%1.0%
LFMDLifeMD, Inc.Mar 2026$3.76M USD+54.2%+61.2%5.4%
ATAIAtai Beckley Inc.Jun 2026$771K USD-5.7%+149.2%0.3%
Peer median (excluding PLSE) —+26.0%+46.8%2.5%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.61M61.14M44.37M118.04M80.74M
Short-term Investments00000
Net Receivables61K000274K
Inventory5.82M000136K
Other Current Assets01.01M963K1.41M2.28M
Total Current Assets36.63M62.15M45.33M119.45M83.42M
Property, Plant & Equipment (Net)11.25M10.02M8.78M8.32M7.06M
Goodwill2.79M2.79M2.79M2.79M2.79M
Intangible Assets3.22M2.55M1.89M1.22M575K
Long-term Investments(3.26M)(2.73M)1.89M00
Tax Assets3.26M2.73M001.58M
Other Non-current Assets365K365K(1.52M)677K691K
Total Non-current Assets17.62M15.73M13.83M13.01M12.69M
Total Assets54.25M77.88M59.15M132.46M96.11M
Account Payables2.9M1.57M1.84M1.67M2.78M
Short-term Debt436K917K001.57M
Tax Payables00000
Deferred Revenue16K0000
Other Current Liabilities1.46M50K3.2M1.2M1.6M
Total Current Liabilities8.52M5.98M6.71M10.06M7.92M
Long-term Debt065M000
Deferred Tax Liabilities00001.58M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities10.04M74.14M8.09M7.54M7.54M
Total Liabilities18.56M80.13M14.79M17.6M15.46M
Common Stock29K37K55K66K68K
Retained Earnings(236.2M)(294.71M)(336.92M)(390.5M)(463.28M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity35.69M(2.25M)44.36M114.86M80.66M
Total Debt11.25M75.96M9.14M8.9M7.53M
Net Debt(17.36M)14.82M(35.22M)(109.14M)(73.21M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.